AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. is trading at $10.87, down 2.95% on the session. The 50 day average sits at $6.62 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 83.9, which reads as overbought, and MACD is bullish crossover. Volume is above average.

The nearest support is around $5.02 with resistance near $11.50, so that band frames the current range. Average daily movement is roughly $0.80, or about 7.4% of the share price, which is what any stop placement has to allow for. The overall health score of 59 out of 100 combines a trend score of 75, momentum of 66 and a risk score of 22.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.